Latest Observability News

Viva Leisure has taken a strategic 33% stake in Gorilla X Labs, aiming to deepen its footprint in the sports nutrition market and enhance member offerings across its platforms.

Nimy Resources has identified a new outcropping chlorite schist 480 metres east of its initial gallium discovery at Block 3, prompting an accelerated drilling program to explore this promising extension.

WiseTech Global has announced a $2.1 billion acquisition of US-based e2open, aiming to create a comprehensive global trade and logistics marketplace. The deal, fully debt-funded and expected to close in the first half of 2026, promises to expand WiseTech’s product suite, customer base, and market reach.

Focus Minerals has agreed to sell its Laverton Gold Project to Genesis Minerals for A$250 million in cash, aiming to boost shareholder value and fund ongoing operations.

Immutep’s novel immunotherapy combination with radiotherapy and KEYTRUDA® has met its primary endpoint in a Phase II trial for resectable soft tissue sarcoma, showing promising early signs of improved patient outcomes.

Lykos Metals announces key leadership changes with David Wheeler stepping up as Non-Executive Chair and Petar Tomasevic taking the helm as Interim CEO, signaling a strategic pivot as the company advances in the Balkan region.

FMR Resources has reported promising assay results from its inaugural drilling at the Demoiselle prospect, revealing extensive copper-silver mineralisation and a new geological model to guide further exploration in Canada’s Fairfield Project.

Askari Metals has completed due diligence on its acquisition of the Adola Greenstone Belt Gold Projects in Ethiopia, positioning itself for growth in a prolific but underexplored gold region.

betr Entertainment has successfully closed the retail portion of its $130 million equity raise, securing funds to advance its strategic acquisition of PointsBet Holdings.

Constellation Resources has withdrawn its initial entitlement offer and launched a revised plan to raise $2.52 million by issuing new shares at a lower price, aiming to fund exploration and working capital.

Zelira Therapeutics has published full results from a Phase I study showing its cannabinoid-based therapy ZLT-L-007 significantly outperforms Lyrica® in managing diabetic neuropathy pain and related symptoms.

Chimeric Therapeutics has progressed its CHM CDH17 CAR-T cell therapy clinical trial to Dose Level 2 after completing Dose Level 1 with no safety concerns, showing encouraging early signs of activity in advanced gastrointestinal cancers.